非小细胞肺癌抗PD-1治疗进展后研究背景与分析.pdfVIP

FDAAnalysis:MetastaticNSCLC

TreatedWithAnti–PD-1Therapy

PastRECISTProgression

CCOtConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisantmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,

Incyte,Merck,andTaihoPharmaceuticals.

Anti–PD-1TherapyPastP